Table 2.
Profile | Proportion of benefited patients by EHL rFVIII (%) |
---|---|
Bleeding profile | 30 - 40 |
Unfavourable PK | 30 - 40 |
Low adherence | 10 - 15 |
High daily activity | 10 - 15 |
PK: pharmacokinetics; EHL: Extended half-life; rFVIII: recombinant factor VIII.